Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC.
Rosano GM, Lewis B, Agewall S, Wassmann S, Vitale C, Schmidt H, Drexel H, Patak A, Torp-Pedersen C, Kjeldsen KP, Tamargo J. Rosano GM, et al. Among authors: wassmann s. Eur Heart J. 2015 Oct 21;36(40):2677-80. doi: 10.1093/eurheartj/ehv161. Epub 2015 May 6. Eur Heart J. 2015. PMID: 25948737 Review. No abstract available.
Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke.
Sulzgruber P, Wassmann S, Semb AG, Doehner W, Widimsky P, Gremmel T, Kaski JC, Savarese G, Rosano GMC, Borghi C, Kjeldsen K, Torp-Pedersen C, Schmidt TA, Lewis BS, Drexel H, Tamargo J, Atar D, Agewall S, Niessner A. Sulzgruber P, et al. Among authors: wassmann s. Eur Heart J Cardiovasc Pharmacother. 2019 Jul 1;5(3):171-180. doi: 10.1093/ehjcvp/pvz016. Eur Heart J Cardiovasc Pharmacother. 2019. PMID: 31119266 Review.
The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials.
Drexel H, Rosano GMC, Lewis BS, Huber K, Vonbank A, Dopheide JF, Mader A, Niessner A, Savarese G, Wassmann S, Agewall S. Drexel H, et al. Among authors: wassmann s. Eur Heart J Cardiovasc Pharmacother. 2020 Apr 1;6(2):97-103. doi: 10.1093/ehjcvp/pvz029. Eur Heart J Cardiovasc Pharmacother. 2020. PMID: 31298686 Free article. Review.
Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases.
Savarese G, Reiner MF, Uijl A, D'Amario D, Agewall S, Atar D, Baumgartner I, Borghi C, De Carlo M, Drexel H, Kaski JC, Kjeldsen KP, Kucher N, Lund LH, Niessner A, Semb AG, Schmidt TA, Sulzgruber P, Tamargo J, Vitale C, Wassmann S, Aboyans V, Lewis BS. Savarese G, et al. Among authors: wassmann s. Eur Heart J Cardiovasc Pharmacother. 2020 Apr 1;6(2):86-93. doi: 10.1093/ehjcvp/pvz036. Eur Heart J Cardiovasc Pharmacother. 2020. PMID: 31392312 Free article.
Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.
Hollan I, Ronda N, Dessein P, Agewall S, Karpouzas G, Tamargo J, Niessner A, Savarese G, Rosano G, Kaski JC, Wassmann S, Meroni PL. Hollan I, et al. Among authors: wassmann s. Eur Heart J Cardiovasc Pharmacother. 2020 Apr 1;6(2):104-114. doi: 10.1093/ehjcvp/pvz033. Eur Heart J Cardiovasc Pharmacother. 2020. PMID: 31397840 Review.
Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1.
Sulzgruber P, Wassmann S, Semb AG, Doehner W, Widimsky P, Gremmel T, Kaski JC, Savarese G, Rosano GMC, Borghi C, Kjeldsen K, Torp-Pedersen C, Schmidt TA, Lewis BS, Drexel H, Tamargo J, Atar D, Agewall S, Niessner A. Sulzgruber P, et al. Among authors: wassmann s. Eur Heart J. 2019 Sep 21;40(36):3010-3012. doi: 10.1093/eurheartj/ehz650. Eur Heart J. 2019. PMID: 31541549 No abstract available.
The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials.
Drexel H, Lewis BS, Rosano GMC, Saely CH, Tautermann G, Huber K, Dopheide JF, Kaski JC, Mader A, Niessner A, Savarese G, Schmidt TA, Semb A, Tamargo J, Wassmann S, Per Kjeldsen K, Agewall S, Pocock SJ. Drexel H, et al. Among authors: wassmann s. Eur Heart J Cardiovasc Pharmacother. 2021 Sep 21;7(5):453-459. doi: 10.1093/ehjcvp/pvaa126. Eur Heart J Cardiovasc Pharmacother. 2021. PMID: 33135079 Review.
The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
Magavern EF, Kaski JC, Turner RM, Drexel H, Janmohamed A, Scourfield A, Burrage D, Floyd CN, Adeyeye E, Tamargo J, Lewis BS, Kjeldsen KP, Niessner A, Wassmann S, Sulzgruber P, Borry P, Agewall S, Semb AG, Savarese G, Pirmohamed M, Caulfield MJ. Magavern EF, et al. Among authors: wassmann s. Eur Heart J Cardiovasc Pharmacother. 2022 Jan 5;8(1):85-99. doi: 10.1093/ehjcvp/pvab018. Eur Heart J Cardiovasc Pharmacother. 2022. PMID: 33638977
Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
Krogager ML, Kragholm K, Thomassen JQ, Søgaard P, Lewis BS, Wassmann S, Baumgartner I, Ceconi C, Schmidt TA, Kaski JC, Drexel H, Semb AG, Agewall S, Niessner A, Savarese G, Kjeldsen KP, Borghi C, Tamargo J, Torp-Pedersen C. Krogager ML, et al. Among authors: wassmann s. Eur Heart J Cardiovasc Pharmacother. 2021 Nov 3;7(6):557-567. doi: 10.1093/ehjcvp/pvab038. Eur Heart J Cardiovasc Pharmacother. 2021. PMID: 33956964 Review.
Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy.
Drexel H, Pocock SJ, Lewis BS, Saely CH, Kaski JC, Rosano GMC, Tautermann G, Huber K, Dopheide JF, Mader A, Niessner A, Savarese G, Schmidt TA, Semb AG, Tamargo J, Wassmann S, Clodi M, Kjeldsen KP, Agewall S. Drexel H, et al. Among authors: wassmann s. Eur Heart J Cardiovasc Pharmacother. 2022 May 5;8(3):302-310. doi: 10.1093/ehjcvp/pvab048. Eur Heart J Cardiovasc Pharmacother. 2022. PMID: 34180504 Review. No abstract available.
100 results